Literature DB >> 8145913

Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group.

R Tawil1, M P McDermott, J R Mendell, J Kissel, R C Griggs.   

Abstract

Faciscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant disorder with a characteristic distribution of weakness and variable severity. Prospective, longitudinal data on FSHD are essential for the design of therapeutic trials and in assessment of genetic heterogeneity. We enrolled 32 well-defined FSHD patients and 32 normal subjects in a natural history study of FSHD. All subjects underwent baseline quantitative muscle testing (QMT), manual muscle testing (MMT), and functional testing. QMT demonstrated substantial weakness in muscles usually spared in FSHD. Major right/left side-to-side differences in strength were documented but, unexpectedly, were not related to handedness. Using the QMT data on normal subjects, we developed regression models relating strength to age, gender, and height and used these models to standardize QMT measurements in FSHD patients, expressing them as the number of SDs from average normal performance. This model-based strategy should facilitate the construction of composite scores to describe the natural history of FSHD and could be useful for constructing sensitive measures of progression in other neuromuscular diseases.

Entities:  

Mesh:

Year:  1994        PMID: 8145913     DOI: 10.1212/wnl.44.3_part_1.442

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Clinical features of facioscapulohumeral muscular dystrophy 2.

Authors:  J C de Greef; R J L F Lemmers; P Camaño; J W Day; S Sacconi; M Dunand; B G M van Engelen; S Kiuru-Enari; G W Padberg; A L Rosa; C Desnuelle; S Spuler; M Tarnopolsky; S L Venance; R R Frants; S M van der Maarel; R Tawil
Journal:  Neurology       Date:  2010-10-26       Impact factor: 9.910

2.  MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.

Authors:  Leo H Wang; Seth D Friedman; Dennis Shaw; Lauren Snider; Chao-Jen Wong; Chris B Budech; Sandra L Poliachik; Nancy E Gove; Leann M Lewis; Amy E Campbell; Richard J F L Lemmers; Silvère M Maarel; Stephen J Tapscott; Rabi N Tawil
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

3.  Reachable workspace reflects dynamometer-measured upper extremity strength in facioscapulohumeral muscular dystrophy.

Authors:  Jay J Han; Evan De Bie; Alina Nicorici; Richard T Abresch; Ruzena Bajcsy; Gregorij Kurillo
Journal:  Muscle Nerve       Date:  2015-06-19       Impact factor: 3.217

4.  Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors:  Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

5.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  James E Hilbert; John T Kissel; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Donald B Sanders; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Contemp Clin Trials       Date:  2011-11-26       Impact factor: 2.226

6.  Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies.

Authors:  Jeffrey M Statland; Bharati Shah; Don Henderson; Silvere Van Der Maarel; Stephen J Tapscott; Rabi Tawil
Journal:  Muscle Nerve       Date:  2015-06-18       Impact factor: 3.217

7.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

Review 8.  Distal myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

Review 9.  Facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey Statland; Rabi Tawil
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

10.  Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey M Statland; Michael P McDermott; Chad Heatwole; William B Martens; Shree Pandya; E L van der Kooi; John T Kissel; Kathryn R Wagner; Rabi Tawil
Journal:  Neuromuscul Disord       Date:  2013-02-11       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.